The largest community of pharma leaders

Minerva Neurosciences’ schizophrenia drug misses main goal in study

(Reuters) – Drug developer Minerva Neurosciences Inc said on Friday its experimental drug for schizophrenia did not meet the main goal of a late-stage study, sending its shares down nearly 66% in early trade.

The drug, roluperidone, did not show statistically significant difference from the placebo in reducing disease symptoms after 12 weeks of treatment, although it was well tolerated during the course of the study, the company said.

Minerva intends to consult with the U.S. Food and Drug Administration about the next steps of development, it said in a statement.

Schizophrenia, which affects about 2.4 million adults in the United States, is a chronic mental disorder that causes distortion in thoughts, hallucinations, and feelings of fright and paranoia.

Existing anti-psychotic drugs in the market include Rexulti from Danish drugmaker H. Lundbeck A/S and Japan’s Otsuka Pharmaceutical Co Ltd, as well as Allergan Plc’s Vraylar, Johnson & Johnson’s Invega and Intra-Cellular Therapies’ Caplyta.

Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Anil D’Silva

Source

Recent Articles

Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

WOBURN, Mass.--(BUSINESS WIRE)--Javelin Biotech today announces a 3-year collaboration with Pfizer...

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

DENVER & CHICAGO--(BUSINESS WIRE)-- #TollLikeReceptor--TriSalus Life Sciences announces its therapeutic clinical...

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that...

VBI Vaccines to Present at Upcoming Scientific Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage...

Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion Announces FDA Clearance of IND...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.